anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain an agent for oral administration having masked bitter taste by mixing a quinolone derivative having antibacterial activity with a higher fatty acid and heating the mixture. SOLUTION: This agent is produced by mixing a quinolone derivative with at least one higher fatty acid, optionally adding an additive, heating the mixture at 30-140 deg.C, preferably at 50-85 deg.C and crushing to powder or granule after cooling. The weight ratio of the quinolone derivative to the fatty acid is 1:(0.3-4). The quinolone derivative is e.g. levofloxacin or ofloxacin and the fatty acid is a &gt;=10C acid such as stearic acid or palmitic acid. A drug preparation necessary to eliminate the taste of an active compound such as soluble tablet, chewable agent and sachet is produced and the active antibacterial quinolone derivative is quickly released by this process. The agent is useful for the treatment of bacteriosis.
The present invention provides a new type spraying agent &#39;biological active spraying agent&#39; which is prepared from raw material of Chinese traditional medicine and technology of bio-fermentation for treating and preventing asthma. The spraying agent is the extract juice processed by bio-fermentation technology with raw material suncured ginseng. The Chinese traditional medicine bio-fermentation agent majors breakthrough in treating asthma. Patient can relieve a cough after inhalation 5-15 minutes. The spraying agent has advantage of micro-method Chinese traditional medicine after processed by bio-fermentation technology, each spray inhalation amount contains 0.03-0.09g of raw medicine, and enhances treating effect of compount Chinese traditional medicine, saves the Chinese traditional medicine resource. The spraying agent has merits of convenient administration, convenient carrying, good taste, good color, non-toxic side effect, low cost, suitable for all. The spraying agent can single treat asthma whole course, and eliminates the dependency to glucocorticoids and antibiotics. The spraying agent is a great invention in medicine research field.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new polymer-platinum compound having anti-tumor activity in vivo.  &lt;P&gt;SOLUTION: A polymer-platinum compound for use in tumor treatment is described. The compound is composed of a polymer backbone having platinum-containing side chains disposed at intervals along the polymer backbone. These side chains are composed of an oligopeptide attached at one end to the backbone and at the other end to the platinum compound. In one aspect, the invention includes a composition for use in a tumor treatment, which contains a polymer-platinum complex compound designed so as to accumulate at the tumor site.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a uterus treatment instrument capable of providing higher medicinal effects.  &lt;P&gt;SOLUTION: The uterus treatment instrument comprises a medicament releasing part 20 in contact with a cervical canal 100 for releasing danazol, a detachment preventive part 30 in contact with an endometrium 120 for preventing detachment of the medicament releasing part 20 from the cervical canal 110, and a tail part 40 with one end 41 attached to the detachment preventive part and the other end 42 exposed from the medicament releasing part 20. The medicament releasing part 20 is a rod-like member with elasticity made of a resin including danazol. The detachment preventive part 30 comprises a base shaft 31 and a branch shaft 32 with the root disposed on the base shaft 31 and the distal end brought into contact with the endometrium 120. The branch shaft 32 is formed slantingly to the base shaft 31 so that the branch shaft comes closer to the base shaft 31 as separated from the medicament releasing part 20.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention provides improved cell delivery compositions. In particular, the invention provides biocompatible endosomolytic agents. In a preferred embodiment, the endosomolytic agents are also biodegradable and can be broken down within cells into components that the cells can either reuse or dispose of. Preferred endosomolytic agents include cationic polymers, particularly those comprised of biomolecules, such as histidine, polyhistidine, polylysine or any combination thereof. Other exemplary endosomolytic agents include, but are not limited to, other imidazole containing compounds such as vinylimidazole and histamine. More particularly preferred are those agents having multiple proton acceptor sites and acting as a &#39;proton sponge&#39;, disrupting the endosome by osmolytic action. In preferred embodiments, the endosomolytic agent comprises a plurality of proton acceptor sites having pKas within the range of 4 to 7, which endosomal lysing component is polycationic at pH 4. The present invention also contemplates the use of these endosomolytic agents as delivery agents by complexation with the desired compound to be delivered. Thus, the present invention also acts as a cell delivery system comprising an endosomolytic agent, a delivery agent, and a compound to be delivered.
PROBLEM TO BE SOLVED: To obtain the particles having high biocompatibility and low irritation and not lowering the effect by providing a core part of a polymer containing an ultraviolet light-protecting agent and a shell part comprising a specific compound not containing the ultraviolet light protecting agent on the surface. SOLUTION: The particles are obtained by providing a core part comprising a polymer containing an ultraviolet light protecting agent and a shell part comprising a polyamino acid not containing ultraviolet light formed on the surface. For example, 4-t-butyl-4&#39;-methoxy-dibenzoylmethane or titanium oxide is preferably used as the ultraviolet light protecting agent. For exmaple, styrene or vinyl acetate is used as the monomer forming the polymer of the core part. The ultraviolet light protecting agent is preferably used in an amount of 5-500 pts.wt., especially about 10-200 pts.wt. based on 100 pts.wt. polymer forming the core part. The shell part is obtained by carrying out emulsion polymerization of α-amino acid-N-carbonic acid anhydride in the presence of ultraviolet light- protecting agent-containing polymer particles forming the core.  A weight ratio of the core part with the shell part is preferably about (1,000:1) to (2:1).
PURPOSE:To manufacture a titled compd. carrying a trace of mineral constituents contained in seawater by bringing fine particles of a precursor of the objective substance such as hydrated oxides and silicates into contact with seawater, and mixing and reacting the obtained material as a starting material. CONSTITUTION:In the manufacture of the titled compd. by mixing and reacting sources of silica, alumina, and magnesium, fine particles, which are formed of an aq. soln. contg. &gt;=1 kind among the above-mentioned raw materials (e.g. hydrated oxides such as hydrated silica, hydrated alumina, and hydrated magnesia, and magnesium silicate, aluminum silicate etc.), are brought into contact with seawater to carry traces of mineral constituents [alkaline(earth) metal, B, Fe, Cu, Mo etc.]. Then the material including said carried material is mixed and reacted to manufacture the titled compd. carrying a trace of mineral constituents which are available for multipurpose uses such as medical anti-acid preparations, a carrier of medicines, a food additive, a feed additive, and cosmetics.
The invention establishes a set of nutritional profiles in a data processing system, which are utilized to establish an optimal meal menu for a given time and location and with regard to a set of available ingredients. The invention includes a profiling routine where a set of characteristics of a particular individual is entered.  The characteristics are aggregated with data saved for other patrons. When an individual with an established profile enters a networked eatery, they initiate a menu routine by entering their identification. The routine matches the information with the aggregated data to determine a patron match, which in turn is matched with the set of characteristics to determine an optimal menu plan. The optimal menu plan is matched with the set of available ingredients to produce a menu. Selected menu items are recorded to the patron&#39;s nutritional profile which can be visually represented in any of several formats.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an application of AMPK-related phosphoenzyme 5.  &lt;P&gt;SOLUTION: A novel member of the human AMPK (a human homolog of sucrose-non-fermenting protein kinase) family is identified and called ARK5 (AMPK-Related Kinase 5). In a nutrient starvation state, ARK5 supports the survival of cells depending on Akt. Further, a PANC-1 cell line (P/ARK cell line) in which PANC-1 is stably transfected by ARK5 exhibits an increase of in vitro transferred activity by more than two times the human pancreas cancer cell line PANC-1. In a nude mouse, the P/ARK cell line exhibits an increase of tumor multiplication by more than 10 times at 12 weeks after transplantation and in the P/ARK cell line, the necrosis region in the transplanted tumor nest is significantly decreased compared to the parent PANC-1 cell line. Furthermore, in the P/ARK cell line transplanted nude mouse, muscle infiltration and mesenterial transference are remarkably observed.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Formation of adhesions, which is a process in which adjacent tissues or organs bind to each other, can be caused by infections, inflammation diseases, surgery procedures or trauma. Following abdominal surgery, the incidence of the formation of adhesions may be as high as 90%. Pain, discomfort, immobility and retarded wound healing are common complications due to adhesions formation; moreover, depending on the tissues involved, adhesions can cause various disorders. In the eye, adhesion of the iris to the lens can lead to glaucoma. In the intestines, adhesions can cause partial or complete bowel obstruction which is life threatening. Intrauterine adhesions are known as the Asherman syndrome. Pelvic adhesions can lead to infertility and reproductive problems. Problems associated with adhesions often require a further operative procedure in order to remove the adhesions. This could have the major drawback of leading to new adhesion formation. A wide variety of adjunctive treatments have been investigated to reduce or prevent post surgical adhesions. Most of these treatments, however, show inconsistent results. In an attempt to reduce the inflammatory reaction at the wounded site following surgery, the use of corticosteroids, NSAIDS, histamine antagonists and calcium channel blockers have been investigated. More recently, barrier materials have been suggested for the prevention of post surgical adhesions. These include, but are not limited to, Hyskon®, Ringer&#39;s lactate, Interceed® (oxidized regenerated cellulose), Polaxamer 407® (temperature dependent polymer), Gore-Tex® (expanded polytetrafluorethylene) and SepraFilm® (hyaluronic acid derivative film).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a pigment prepared by coating the surface of a layered alkali metal polysilicate with a metal oxide; to provide a pearl pigment at a low price whose size and shape are easily controlled; and to provide a composition comprising the pearl pigment prepared by coating the surface of a layered alkali metal polysilicate with a metal oxide.  &lt;P&gt;SOLUTION: The pigment comprises a layered alkali metal polysilicate as a substrate, wherein the surface thereof is coated with a metal oxide. The layered alkali metal polysilicate can include sodium salts such as makatite, ilerite, magadiite, and kenyaite. The metal oxide can include titanium oxide, iron oxide and the like. The pearl pigment preferably has an average particle size of 2-200 μm and an average thickness of 0.01-5 μm.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Crude sapogenin-containing material, obtained by hydrolysis of natural saponin-containing material and containing coloured impurities, is purified by heating it with a solution of an alkali metal hydroxide or an alkali metal alkoxide (derived from an alkanol which contains from one to five carbon atoms) in such an alkanol, preferably methanol, to effect at least partial hydrolysis of coloured impurities, treating the reaction mixture with alkaline earth metal ions to precipitate at least some of the coloured impurities, and separating the alkanolic solution containing dissolved sapogenin.  The preferred starting material is a &#34;dried sludge&#34; obtained by acid hydrolysis of the sap expressed from plant material, the hydrolysis being preceded if desired by autolysis due to enzymes in the sap, and preferably removing the excess acid by washing or with sodium carbonate. When derived from sisal the sludge contains from 5-30 per cent hecogenin.  The sapogenin may be recovered from the alkanolic solution by crystallization and then further purified, e.g. by extraction with a hydrocarbon solvent containing aliphatic hydrocarbons of 6-12 carbons per molecule, or by acetylation procedures.  The preferred source of alkaline earth ions is calcium chloride or acetate which are alkanol-soluble.  In examples: (1) Kenyan &#34;dried sludge&#34; containing hecogenin is refluxed with methanol and sodium hydroxide, the mixture stirred with calcium chloride, filtered and filtrate concentrated, solid sodium chloride separated and solution cooled yielding crude hecogenin, which is slurried with light petroleum to remove impurities, and dried; (2) as in (1) using calcium acetate as the source of calcium ions; (3) and (4), as in (1), using &#34;dried sludge&#34; of Tanganyikan and Jamaican origin; (5) and (6) as in (1), using sodium in methanol and potassium hydroxide in n-butanol respectively as the hydrolysing agents. Specifications 768,459 and 784,536 are referred to.
PURPOSE: A composition for regulating growth of nerve cells containing coprisin peptide derivative, CopA3(9-mer disulfide dimer), as an active ingredient is provided to be used as a therapeutic agent for treating neurodegenerative diseases such as Alzheimer&#39;s diseases or Parkinson&#39;s disease without side effects. CONSTITUTION: A composition for regulating growth of nerve cells contains a coprisin peptide derivative, CopA3(9-mer disulfide dimer), with an amino acid sequence. The derivative is a regulator which promotes growth of nerve cells or suppresses programmed cell death of nerve cells. The nerve cells are brain cells. The derivative is D-type and is derived from an insect. The derivative is used for treating neurodegenerative diseases such as Alzheimer&#39;s disease, Parkinson&#39;s disease, or Huntington&#39;s disease.
1452701 Psychotropic compositions containing 2-substituted morpholines IMPERIAL CHEMICAL INDUSTRIES Ltd 9 April 1975 [7 May 1974] 20013/74 Heading A5B [Also in Divisions C2C and C2P] Pharmaceutical compositions having psychotropic activity comprise, as active ingredient, a 2-substituted morpholine of the general formula: wherein A is -CH 2 CH 2 - or -CH=CH- and X is a phenyl group optionally bearing one or two substituents selected from halogen atoms and C 1-6  alkyl, C 1-6  alkoxy and C 6-10  aryloxy groups, the aryloxy groups themselves being optionally substituted by one or two substituents selected from halogen atoms and C 1-4  alkyl groups, or a pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier or diluent and optionally one or more known drugs selected from neuroleptic-sedative agents, e.g. chlorpromazine, prochlorperazine, trifluoperazine and haloperidol; other sedative drugs and tranquillizers, e.g. chlordiazepoxide, phenobarbitone and amylobarbitone; #-adrenergic blocking agents, e.g. propanolol; drugs used in the treatment of Parkinson&#39;s disease, e.g. benzhexol; and other antidepressant drugs, e.g. imipramine, desipramine, amitriptyline and nortriptyline; drugs of the amphetamine type; and monoamineoxidase inhibitors, e.g. phenelzine and mebanazine. They may be administered orally or parenterally in the form of tablets, capsules, aqueous or oily solutions or suspensions, emulsions, sterile injectable aqueous or oily solutions or suspensions, or dispersible powders.
To enable a report to be opened by a user other than a doctor-in-charge, and prevent the report from being inadvertently opened.SOLUTION: A browse screen 700 displays the content of a report R1. A requester for the report R1 is a user U1. The profession of a user U3 who requested browsing of the report R1 is an &#34;intern&#34;, and is included in the professions &#34;doctor, intern&#34; allowed to open the report R1. However, the user U3 is different from the requester (user U1) for the report R1. Therefore, the user U3 who requested browsing of the report R1 has the right to open the report R1 and is a user other than the doctor in charge of a patient. In this case, when displaying the browse screen 700 in accordance with the request for browsing the report R1, an information processing device displays an inquiry message 701 on the browse screen 700 as to whether or not to put the report R1 in a confirmed state.SELECTED DRAWING: Figure 7
&lt;P&gt;PROBLEM TO BE SOLVED: To produce chondroitin sodium sulfate and chondroitin sulfate-containing substances at lower cost and in a shorter time as far as possible.  &lt;P&gt;SOLUTION: The chondroitin sodium sulfate is deposited by adding an alcohol to a filtrate of a solution prepared by enzymatic treatment of fish cartilage and by extracting proteins after the solution is filtrated. The chondroitin sodium sulfate thus prepared can be utilized as raw materials of pharmaceuticals, unregulated drugs, pharmaceutical additives, cosmetics and foodstuff additives. As well, the chondroitin sulfate-containing substance is prepared by drying up the filtrate of the solution prepared by enzymatic treatment of the fish cartilage and by extracting the proteins after the solution is filtrated. The chondroitin sulfate-containing substance thus prepared can be utilized e.g. as raw materials of cosmetics and foodstuffs.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;PICT:0974943/C1/1&gt; &lt;PICT:0974943/C1/2&gt; A centrifugal multi-chamber countercurrent exchanger 10 has a shaft 12 journalled for rotation in a suitable supporting structure and a drum or rotor 14 has a plurality of radially extending cavities or mixing chambers 22 and 24 in two vertical planes without communication between them.  Removably positioned in each of the working mixing chambers is a novel disc column, e.g. as shown in Fig. 4, though the chambers may be sealed for idle condition, as shown in Fig. 1, with relation to the mixing chambers 24.  The mixing chambers may also be filled with Raschig rings, Berl saddles, asbestos or glass wool.  The heavy liquid enters the mixing chambers 22 or 24 near the inner end thereof through the heavy liquid inlet tubes 52 while the light liquid enters under pressure near the outer end through the light liquid inlet tubes 60. They travel in countercurrent and pass out through the corresponding outlet 42 and 44 via the common annuli 32 and 3. Specifications 963,166 and 974,942 are referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method which is inexpensive and packages a solution containing a protein, and also to provide a container which is obtained.  &lt;P&gt;SOLUTION: A flexible polymeric container holds albumin. The container (12) is made of a sheet of a flexible polymeric film (34) formed into a bag. The flexible polymeric container has a cavity which is surrounded by a first wall, an opposing second wall, and seals about a periphery of these first and second walls. The seals join the inner parts of the opposing first and second walls, and create a fluid-tight chamber for storing the albumin with a certain concentration in the cavity of the container. The method for packaging the albumin protein in the flexible polymeric container is provided. A flexible polymeric material is converted into the bags, and a certain amount of the albumin is filled into the bag with a filling appliance (44) and the albumin is stored in the bag by sealing the sealing area of the bag.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To produce high purity tetracalcium phosphate with a comparatively simple process by heating an aqueous suspension of equimolar powdery CaHPO4 .2H2 O and fine powder CaCO3 to a specified temp., maintaining the suspension at this temp. to form a reaction product and calcining the reaction product. SOLUTION: In this production, powder CaHPO4 .2H2 O and fine powder CaCO3 are mixed together in a molar ratio of 1:1 to form an aqueous suspension and thereafter, the resulting suspension is heated to a temp. above 70 deg.C and maintained at this temp. to allow it to react to form a reaction product and then, the reaction product is calcined to produce the objective tetracalcium phosphate. As the CaCO3 used, it is required to use particles as fine as possible. When the particle size of CaCO3 is large, the reaction proceeds insufficiently at a temp. above 70 deg.C and unreacted powdery CaCO3 , remains in the reaction product. From this viewpoint, CaCO3 fine particles having a &lt;=5μm average particle size are preferred as the fine powder CaCO3 .
A system and method is disclosed whereby a health care provider is offered a benefit in exchange for the performance of specified activities of a patient. The patient activities may take the form of a purchase of prescribed or recommended products or services, such as prescription drugs, undergoing prescribed or recommended health care procedures, or participation in health-oriented programs or activities, such as a specified exercise regimen. In one embodiment, a benefit is provided to a health care provider upon verification of the adherence of a patient to a specified health-related activity. In one embodiment a benefit is provided to both a provider and a patient upon verification of the patient&#39;s adherence to a specified health-related activity. In one embodiment, patient adherence is facilitated by distributing benefit cards to patients wherein the benefit card identifies the patient as registered in an adherence program and is associated with a benefit account for receiving program benefits. In one embodiment, the benefit card account is associated with the patient&#39;s health or prescription insurance account so as to verify adherence using claims submitted to the patient&#39;s health insurer. In one embodiment, the benefit card operates as a payment card allowing the cardholder to redeem benefits.
PROBLEM TO BE SOLVED: To obtain the subject product capable of temporally dyeing hair while realizing good operability and simpleness by packing a hair cosmetic comprising a specific component as contents into a specific cosmetic container. SOLUTION: This product is obtained by packing a hair cosmetic containing (A) mica titanium, (B) a hair-fixing polymer and (C) water as contents into a cosmetic container provided with a comb capable of jetting the content from the tip region of comb teeth. Further, it is preferable that the hair cosmetic contains a surfactant and a propellant and the cosmetic is jetted as foam from the tip region of comb teeth of the cosmetic container. The component A contains mica titanium having &gt;=20 μm particle diameter in an amount of &lt;=10 vol.% in total amount of the component A and titanium oxide layer of mica titanium surface is rutile type and the mica titanium is preferably contained in n amount of 0.5-10 wt.% based on hair cosmetic.  The component B is preferably contained in an amount of 10-100 pts.wt. based on 100 pts.wt. component A and in an amount of 0.05-10 wt.% based on the hair cosmetic.